RESUMO
Treating respiratory distress is a priority when managing critically ill patients. Non-invasive ventilation (NIV) is increasingly used as a tool to prevent endotracheal intubation. Providing oral or enteral nutritional support during NIV may be perceived as unsafe because of the possible risk of aspiration so that these patients are frequently denied adequate caloric and protein intake. Newly available therapies, such as high-flow nasal oxygen (HFNO) may allow for more appropriate oral feeding.
Assuntos
Dispneia/dietoterapia , Ventilação não Invasiva/tendências , Apoio Nutricional/métodos , Estado Terminal/terapia , Humanos , Ventilação não Invasiva/efeitos adversos , Ventilação não Invasiva/métodos , Insuficiência Respiratória/terapia , Fatores de TempoRESUMO
Pulmonary embolism (PE) is common and the majority of patients survive the acute event. Survivors are at increased risk for adverse outcomes, including persistent thrombi, recurrent embolism, chronic thromboembolic pulmonary hypertension (CTEPH), and death. Anticoagulation protects against recurrence, which has a high mortality rate. The recommended duration of anticoagulation for patients with reversible PE risk factors is 3 months. For patients with idiopathic PE or persistent risk factors, extended duration of anticoagulation is preferred, balanced with an individual patient's risk of hemorrhage, which in itself is a major cause of morbidity and mortality. Among patients with malignancy who develop venous thromboembolism (VTE), low-molecular-weight heparin is preferred over oral vitamin K antagonists in the first 6 months. Thereafter, anticoagulation should be continued indefinitely with either low-molecular-weight heparin or oral vitamin K antagonists. Inferior vena cava filters are not routinely recommended and should only be used in patients who have a contraindication to anticoagulation. Patients who have had VTE and with persistent or recurrent dyspnea should be evaluated for recurrence of VTE or development of CTEPH. Patients with recurrent VTE should be anticoagulated indefinitely. Routine screening for CTEPH in asymptomatic patients is not recommended. Echocardiography often provides the first indication of the presence of pulmonary hypertension. Once presence of CTEPH is established by right-sided heart catheterization and perfusion imaging (ie, ventilation/perfusion scintigraphy, computed tomography angiography, or pulmonary angiography), patients should be referred early to a center with expertise, as it is potentially surgically curable by pulmonary endarterectomy. Those who are deemed inoperable after being evaluated may gain symptomatic benefit from drugs approved for idiopathic pulmonary arterial hypertension. Lung transplantation may also be an option for patients who are not candidates for pulmonary endarterectomy.
Assuntos
Anticoagulantes/uso terapêutico , Embolia Pulmonar/tratamento farmacológico , Anticoagulantes/administração & dosagem , Anticoagulantes/efeitos adversos , Testes de Coagulação Sanguínea , Doença Crônica , Esquema de Medicação , Dispneia/diagnóstico , Dispneia/dietoterapia , Dispneia/etiologia , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/tratamento farmacológico , Hipertensão Pulmonar/etiologia , Neoplasias/complicações , Embolia Pulmonar/complicações , Embolia Pulmonar/diagnóstico , Fatores de Risco , Filtros de Veia Cava , Trombose Venosa/tratamento farmacológico , Trombose Venosa/etiologia , Vitamina K/antagonistas & inibidoresRESUMO
COPD is a progressive illness with worldwide impact. Patients invariably reach a point at which they require palliative interventions. Dyspnea is the most distressing symptom experienced by these patients; when not relieved by traditional COPD management strategies it is termed "refractory dyspnea" and palliative approaches are required. The focus of care shifts from prolonging survival to reducing symptoms, increasing function, and improving quality of life. Numerous pharmacological and non-pharmacological interventions can achieve these goals, though evidence supporting their use is variable. This review provides a summary of the options for the management of refractory dyspnea in COPD, outlining currently available evidence and highlighting areas for further investigation. Topics include oxygen, opioids, psychotropic drugs, inhaled furosemide, Heliox, rehabilitation, nutrition, psychosocial support, breathing techniques, and breathlessness clinics.
Assuntos
Dispneia/tratamento farmacológico , Dispneia/terapia , Cuidados Paliativos , Doença Pulmonar Obstrutiva Crônica/complicações , Analgésicos/uso terapêutico , Exercícios Respiratórios , Dispneia/dietoterapia , Dispneia/fisiopatologia , Medicina Baseada em Evidências , Humanos , Apoio Social , Austrália do SulRESUMO
The effect of a protein-rich diet containing 141 g of protein on the clinical and some biochemical findings in 145 patients with a torpidly, and latently running recurrent rheumatic heart disease was studied. Pertinent observations have shown the protein-rich diet to have a very beneficial effect on the clinico-biochemical and immunological indices that are pathognomic of rheumatism with low activity and torpid course.